Dr. Rahul Baxi highlights that a new Rs 16,000-a-month weight-loss injection isn't a miracle solution without essential ...

Drugs like Ozempic, Wegovy, and Saxenda have become hugely popular. But could they cause psychological side effects in their ...

Not long ago, the FDA announced there's no longer a shortage of Ozempic, Wegovy, Zepbound or similar drugs used for weight ...

Claims data also show rapid adoption of GLP-1 for weight loss, with a steady increase in utilization since 2021 and peaking ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

A large cohort study finds GLP-1 receptor agonists linked to lower graft loss and mortality in kidney transplant recipients ...

Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

The company also suffered from a clinical setback that sank its stock price. However, the stock now looks reasonably valued, ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Those in favor of the classification argue that excess fat accumulation/distribution is linked to sustained and serious ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.